


# World Summit AI Americas Presentation

Louis A. Young II  
Founder & CEO


4/20/2023



**410 BCE**



**1780**




# Respiratory Big Data & AI Demand

Johnson & Johnson

**gsk**  
GlaxoSmithKline

**Roche**

**NOVARTIS**




## The Clarinet



## The Respiratory Cloud Machine

> Individual Data Summary			
Dashboard Individual Data Summary Individual Data Group Data			
Respiratory Profile Vital	Alert	Reading	Implication
Tidal Volume	Normal	6 ml/kg	> 10 ml/kg: increased risk of pulmonary barotrauma < 3 ml/kg: decreased oxygen saturation in blood
Inspiratory Reserve Volume	Normal	1700 ml	< 1500 ml: restrictive diseases like IRDS, pulmonary fibrosis, weak respiratory muscles
Expiratory Reserve Volume	Concern	600 ml	< 600 ml: chronic pulmonary conditions
Residual Volume	Warning	800 ml	< 900 ml: obstructive lung diseases, COPD, asthma, bronchiectasis, etc.
Dead Space Volume	Concern	175 ml	> 200: some lung diseases due to ventilation-perfusion mismatch
Respiratory Rate	Concern	30	The normal respiration rate for an adult at rest is 12-20 breaths per minute. A respiration rate under 12 or over 20 breaths per minute while resting is considered abnormal.
Forced Expiratory Volume	Concern	72%	79-70% - Mildly abnormal; 69-60% - Moderately abnormal; 59-50% - Moderately to severely abnormal; 49-35% - Severely abnormal; Less than 35% - very severely abnormal
Inspiratory Capacity	Concern	2400 ml	< 2400 ml
Functional Residual Capacity	Concern	1600 ml	< 1500 ml in conditions associated with reduced compliance
Vital Capacity / Forced Vital Capacity	Concern	3000 ml	< 3000 ml

# Healthmetryx AI Future





# Our Team

**Louis Young II**



**Founder & CEO**




**Robert Foney**



**CMO**

## Advisors

Includes 4 MDs and 7 PhDs



# Execution Partners



# RCM Real-World Evidence Market Impact



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 10-K

(Mark One)  
☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  
For the fiscal year ended December 31, 2021  
or  
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  
For the transition period from to  
Commission File Number: 001-35997

**IQVIA HOLDINGS INC.**  
**IQVIA**  
(Exact name of registrant as specified in its charter)

Delaware  
(State or other jurisdiction of incorporation or organization)

27-1341991  
(I.R.S. Employer Identification Number)

4820 Emperor Blvd., Durham, North Carolina 27703  
(Address of principal executive office and Zip Code)

(919) 998-2000  
(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.01 per share	IQV	New York Stock Exchange

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐  
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or section 15(d) of the Exchange Act. Yes ☐ No ☒  
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding twelve months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐  
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (17 CFR 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐  
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or



FORBES > INNOVATION > HEALTHCARE

## The Flatiron Health Acquisition Is A Shot In The Arm For Roche's Oncology Real-World Evidence Needs

Reenita Das Former Contributor ⓘ

# Traction



UNIVERSITY OF THE  
WITWATERSRAND,  
JOHANNESBURG

**Unisa**  
Universidade  
de Santo Amaro



**Hospital  
Francisco  
Muñiz**